This monograph reviews the rationale for utilizing HER3 as a novel biomarker and the latest safety and efficacy data of HER3-targeted therapies. The authors discuss how these agents may fit into existing treatment paradigms and highlight optimal use through clinical case discussions, aiming to educate oncology providers on integrating HER3-targeted agents into personalized treatment plans, ultimately improving outcomes for patients with advanced NSCLC.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/oncologyce/lung-cancer/20241023/her3-in-nsclc-navigating-new-frontiers-in-targeted-therapy/overview
- Start Date: 2024-10-01 05:00:00
- End Date: 2024-10-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 47473.93 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest